The Life Sciences team advised Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) on its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Checkmate, are expected to be approximately $75,000,000. Checkmate has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Checkmate is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate’s product candidate, CMP-001, is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies.

The Goodwin team was led by Mitch Bloom, Ben Marsh and Sonia Wu; Kristin Gerber, Katie Hand, Crescent ChasteenJulie Tibbets, Elizabeth Mulkey, Roger Cohen, Nikhil Sethi, Janet Andolina, Matthew Dunay, Caroline Bullerjahn, Carl Metzger, Jackie Klosek and Ettore Santucci, with invaluable assistance from Tricia Hojo and Nathan Needle.

For more details, read the press release and articles in Endpoints and Seeking Alpha.